Cost-Effectiveness of Procalcitonin-Guided Antibiotic Use in Community Acquired Pneumonia
详细信息 查看全文
- 作者：Kenneth J. Smith MD ; MS (1)
Angela Wateska MPH (1)
M. Patricia Nowalk PhD ; RD (2)
Mahlon Raymund PhD (2)
Bruce Y. Lee MD ; MBA (1)
Richard K. Zimmerman MD ; MPH (2)
Michael J. Fine MD ; MSc (1) (3) - 关键词：cost ; effectiveness analysis ; procalcitonin ; community ; acquired pneumonia
- 刊名：Journal of General Internal Medicine
- 出版年：2013
- 出版时间：September 2013
- 年：2013
- 卷：28
- 期：9
- 页码：1157-1164
- 全文大小：427KB
- 参考文献：1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27鈥?2. CrossRef
2. Garcia-Vazquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med. 2004;164:1807鈥?1. CrossRef
3. Reed WW, Byrd GS, Gates RH Jr, Howard RS, Weaver MJ. Sputum gram鈥檚 stain in community-acquired pneumococcal pneumonia. A meta-analysis. West J Med. 1996;165:197鈥?04.
4. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009;22:352鈥?. CrossRef
5. Wenzel RP, Edmond MB. Managing antibiotic resistance. N Engl J Med. 2000;343:1961鈥?. CrossRef
6. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171:1322鈥?1. CrossRef
7. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004;89:1512鈥?5. jc.2002-021444">CrossRef
8. Muller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138:121鈥?. CrossRef
9. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in 鈥淩eal Life鈥? an International, Multicenter Poststudy Survey (ProREAL). Arch Intern Med. 2012;172:715鈥?2. CrossRef
10. Yealy DM, Fine MJ. Measurement of serum procalcitonin: a step closer to tailored care for respiratory infections? JAMA. 2009;302:1115鈥?. jama.2009.1318">CrossRef
11. US Bureau of Labor Statistics. Consumer price index. http://www.bls.gov/cpi/#data (Accessed February 19, 2013)
12. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243鈥?0. CrossRef
13. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377鈥?2. CrossRef
14. Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002;21:303鈥?1. CrossRef
15. Centers for Medicare & Medicaid Services. New Clinical Laboratory Fee Schedule Test Codes. Procalcitonin. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Downloads/CY2011-CLFS-New-Test-Codes.pdf. (Accessed February 19, 2013)
16. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med. 2000;109:378鈥?5. CrossRef
17. Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778鈥?2. CrossRef
18. Coley CM, Li YH, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 1996;156:1565鈥?1. CrossRef
19. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients鈥?care. Lancet. 2003;362:1225鈥?0. CrossRef
20. Sharpe BA. Putting a critical pathway into practice: the devil is in the implementation details: comment on 鈥渆ffect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia鈥漰utting a critical pathway into practice. Arch Intern Med. 2012;172:928鈥?. CrossRef
21. Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis. 2011;53:379鈥?7. CrossRef
22. Layios N, Lambermont B, Canivet JL, et al. Procalcitonin usefulness for the initiation of antibiotic treatment in intensive care unit patients*. Crit Care Med. 2012;40:2304鈥?. CrossRef
23. Fine MJ, Medsger AR, Stone RA, et al. The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 1997;157:47鈥?6. CrossRef
24. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med. 2003;115:343鈥?1. CrossRef
25. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999;159:970鈥?0. CrossRef
26. Carratala J, Garcia-Vidal C, Ortega L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trialA 3-step critical pathway for CAP. Arch Intern Med. 2012;172:922鈥?. jamainternmed.2013.1408">CrossRef
27. Schnoor M, Meyer T, Suttorp N, Raspe H, Welte T, Schafer T. Development and evaluation of an implementation strategy for the German guideline on community-acquired pneumonia. Qual Saf Health Care. 2010;19:498鈥?02. CrossRef
28. Mundy LM, Leet TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest. 2003;124:883鈥?. CrossRef
29. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med. 2001;161:722鈥?. CrossRef
30. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120:783鈥?0. j.amjmed.2007.04.023">CrossRef - 作者单位：Kenneth J. Smith MD, MS (1)
Angela Wateska MPH (1)
M. Patricia Nowalk PhD, RD (2)
Mahlon Raymund PhD (2)
Bruce Y. Lee MD, MBA (1)
Richard K. Zimmerman MD, MPH (2)
Michael J. Fine MD, MSc (1) (3)
1. Department of Medicine, University of Pittsburgh School of Medicine, 200 Meyran Ave, Suite 200, Pittsburgh, PA, 15213, USA
2. Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3. Center for Health Equity and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA
文摘